Forging a position as an innovative player in
infectious disease vaccines and therapies

Home
About
Our Technology
Business Development
- Partner Network
- Licensing Strategy and Available Licenses
Investor Relations
Contact Us
- Corporate directory

BioDiem » » Company Update and EOFY 2018 Information

Company Update and EOFY 2018 Information August 3, 2018 • Category • Author Name

View the announcement here

Latest News

Opal acquisition of Formulytica – Capital raising

May 6, 2021

Opal acquisition of Formulytica – Capital raising

Read More
Opal Biosciences 2021 Information Memorandum

May 6, 2021

Opal Biosciences 2021 Information Memorandum

Read More

Join our email list!

Join our email distribution list to be updated with announcements.

© Copyright 2014 BioDiem

Privacy Policy
Terms and conditions